Literature DB >> 27598516

Immunological effects of chemotherapy and radiotherapy against brain tumors.

Tobias Weiss1, Michael Weller1, Patrick Roth1.   

Abstract

INTRODUCTION: The mainstays of brain tumor therapy are surgery, radiotherapy and chemotherapy. Cancer immunotherapy is explored as an additional treatment modality. However, emerging evidence indicates that also radio- and chemotherapy have immunological effects in addition to their cytotoxic and cytostatic activities. AREA COVERED: We summarize the literature on radio- and chemotherapy-mediated immunological effects in primary and secondary brain tumors and outline open questions within the field. To this end, a literature search was performed using the terms 'brain tumor', 'immune system', 'immunogenic cell death', 'vaccination', 'checkpoint inhibition', 'radiotherapy', 'chemotherapy' and derivations thereof. Expert commentary: Immunological effects of chemo- and radiotherapy in brain tumors involve direct immunogenic modulations of tumor cells, changes of the microenvironment and functional alterations of innate and adaptive immune cells. Each treatment modality can exert various effects that comprise both immune-stimulatory and immunosuppressive mechanisms. A detailed knowledge of these mechanisms is indispensable for an optimal combination of conventional anti-tumor treatments and novel immunotherapeutic approaches.

Entities:  

Keywords:  Radiotherapy; brain tumor; checkpoint inhibition; chemotherapy; glioblastoma; immunogenic cell death; vaccination

Mesh:

Substances:

Year:  2016        PMID: 27598516     DOI: 10.1080/14737140.2016.1229600

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  16 in total

Review 1.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 2.  CAR-armed cell therapy for gliomas.

Authors:  You Zhai; Guanzhang Li; Tao Jiang; Wei Zhang
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

Review 3.  The Microenvironmental Landscape of Brain Tumors.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

Review 4.  Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors:  Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 5.  Near Infrared Light Triggered Photo/Immuno-Therapy Toward Cancers.

Authors:  Xiaoxue Xu; Hongxu Lu; Ruda Lee
Journal:  Front Bioeng Biotechnol       Date:  2020-05-26

Review 6.  Harnessing the immune system in glioblastoma.

Authors:  Nicholas F Brown; Thomas J Carter; Diego Ottaviani; Paul Mulholland
Journal:  Br J Cancer       Date:  2018-11-05       Impact factor: 7.640

Review 7.  Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer.

Authors:  Matthew D Kerr; David A McBride; Arun K Chumber; Nisarg J Shah
Journal:  Expert Opin Drug Discov       Date:  2020-08-31       Impact factor: 6.098

Review 8.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

9.  Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients.

Authors:  Darawan Rinchai; Elena Verzoni; Veronica Huber; Agata Cova; Paola Squarcina; Loris De Cecco; Filippo de Braud; Raffaele Ratta; Matteo Dugo; Luca Lalli; Viviana Vallacchi; Monica Rodolfo; Jessica Roelands; Chiara Castelli; Damien Chaussabel; Giuseppe Procopio; Davide Bedognetti; Licia Rivoltini
Journal:  Clin Transl Med       Date:  2021-06

Review 10.  Immunotherapies for malignant glioma.

Authors:  Vassiliki A Boussiotis; Alain Charest
Journal:  Oncogene       Date:  2017-12-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.